TY - JOUR
T1 - Preclinical good laboratory practice-compliant safety study to evaluate biodistribution and tumorigenicity of a cartilage advanced therapy medicinal product (ATMP)
AU - Zscharnack, Matthias
AU - Krause, Christopsh
AU - Aust, Gabriela
AU - Thümmler, Christian
AU - Peinemann, Frank
AU - Keller, Thomas
AU - Smink, Jeske J.
AU - Holland, Heidrun
AU - Somerson, Jeremy S.
AU - Knauer, Jens
AU - Schulz, Ronny M.
AU - Lehmann, Jörg
N1 - Publisher Copyright:
© 2015 Zscharnack et al.; licensee BioMed Central.
PY - 2015/12/12
Y1 - 2015/12/12
N2 - Background: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of ATMPs under good laboratory practice (GLP) conditions avoiding cell product manipulation. Moreover, the strategy was applied on a human ATMP for cartilage repair. Methods: The testing strategy addresses biodistribution and tumorigenicity using a multi-step analysis without any cell manipulation to exclude changes of test item characteristics. As a safeguard measurement for meeting regulatory expectations, the project design and goals were discussed continuously with the regulatory authority using a staggered scientific advice concept. Subsequently, the strategy was applied to co.don chondrosphere® (huChon spheroid), a tissue-engineered matrix-free ATMP of human normal chondrocytes. In both the biodistribution and tumorigenicity studies, huChon spheroids were implanted subcutaneously into 40 immunodeficient mice. Biodistribution was studied 1 month after implantation. A skin disc containing the huChon spheroid, two surrounding skin rings and selected organs were analyzed by validated, gender-specific, highly-sensitive triplex qPCR and by immunohistochemistry (IHC). Results: No human DNA was detected in distant skin rings and analyzed organs. IHC revealed no direct or indirect indications of cell migration. Tumorigenicity was assessed 6 months after huChon spheroid implantation by palpation, macroscopic inspection, histology and IHC. No mice from the huChon spheroid group developed a tumor at the implantation site. In two mice, benign tumors were detected that were negative for HLA-ABC, suggesting that they were of spontaneous murine origin. Conclusions: In summary, the presented strategy using a multi-step analysis was confirmed to be suitable for safety studies of ATMPs.
AB - Background: The clinical development of advanced therapy medicinal products (ATMPs), a new class of drugs, requires initial safety studies that deviate from standard non-clinical safety protocols. The study provides a strategy to address the safety aspects of biodistribution and tumorigenicity of ATMPs under good laboratory practice (GLP) conditions avoiding cell product manipulation. Moreover, the strategy was applied on a human ATMP for cartilage repair. Methods: The testing strategy addresses biodistribution and tumorigenicity using a multi-step analysis without any cell manipulation to exclude changes of test item characteristics. As a safeguard measurement for meeting regulatory expectations, the project design and goals were discussed continuously with the regulatory authority using a staggered scientific advice concept. Subsequently, the strategy was applied to co.don chondrosphere® (huChon spheroid), a tissue-engineered matrix-free ATMP of human normal chondrocytes. In both the biodistribution and tumorigenicity studies, huChon spheroids were implanted subcutaneously into 40 immunodeficient mice. Biodistribution was studied 1 month after implantation. A skin disc containing the huChon spheroid, two surrounding skin rings and selected organs were analyzed by validated, gender-specific, highly-sensitive triplex qPCR and by immunohistochemistry (IHC). Results: No human DNA was detected in distant skin rings and analyzed organs. IHC revealed no direct or indirect indications of cell migration. Tumorigenicity was assessed 6 months after huChon spheroid implantation by palpation, macroscopic inspection, histology and IHC. No mice from the huChon spheroid group developed a tumor at the implantation site. In two mice, benign tumors were detected that were negative for HLA-ABC, suggesting that they were of spontaneous murine origin. Conclusions: In summary, the presented strategy using a multi-step analysis was confirmed to be suitable for safety studies of ATMPs.
KW - ATMP
KW - Biodistribution
KW - Cartilage repair
KW - Chondrocytes
KW - Safety
KW - Tumorigenicity
UR - http://www.scopus.com/inward/record.url?scp=85019191851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019191851&partnerID=8YFLogxK
U2 - 10.1186/s12967-015-0517-x
DO - 10.1186/s12967-015-0517-x
M3 - Article
C2 - 25990108
AN - SCOPUS:85019191851
SN - 1479-5876
VL - 13
JO - Journal of Translational Medicine
JF - Journal of Translational Medicine
IS - 1
M1 - 160
ER -